CVS Group plc Block Listing Interim Review and TVR Update (4416M)

TIDMCVSG

RNS Number : 4416M

CVS Group plc

11 January 2023

CVS Group plc

("CVS" or the "Company")

Block Listing Interim Review and TVR Update

CVS, one of the UK's leading providers of integrated veterinary services, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements. References to securities are to the Company's ordinary shares of 0.2 pence each ("Ordinary Shares").

 
 Name of the company:            CVS Group plc 
 Name of relevant scheme:             1. CVS Group plc 2017-2020 Sharesave Scheme; 
                                       2. CVS Group plc 2018-2021 SAYE Sharesave 
                                       Scheme; and 
                                       3. CVS Group 2018 SAYE Plan 
                                ------------------------------------------------------ 
 Period           From:          12 July 2022             To:    11 January 2023 
  of return: 
                 -------------  -----------------------  -----  ---------------------- 
 Balance of unallotted                1. 230 
  securities under scheme(s) 
  from previous return: 
                                       2. 19,598 
                                       3. 348,290 
                                ------------------------------------------------------ 
 Plus: The amount by                  1. Nil 
  which the block scheme(s)            2. Nil 
  has been increased                   3. Nil 
  since the date of 
  the last return (if 
  any increase has been 
  applied for): 
                                ------------------------------------------------------ 
 Less: Number of securities           1. 0 
  issued / allotted 
  under scheme(s) during 
  period: 
                                       2. 6,734 
                                       3. 112,148 
                                ------------------------------------------------------ 
 Equals: Balance under                1. 230 
  scheme(s) not yet 
  issued / allotted 
  at end of period: 
                                       2. 12,864 
                                       3. 236,142 
                                ------------------------------------------------------ 
 Number and class of                  1. 114,302 Ordinary Shares admitted on 
  securities originally                11 January 2021 and 1,535 Ordinary Shares 
  listed and the date                  admitted on 1 September 2021 
  of admission:                        2. 296,069 Ordinary Shares admitted on 
                                       1 September 2021 
                                       3. 350,000 Ordinary Shares admitted on 
                                       30 December 2021 
                                ------------------------------------------------------

Total Voting Rights

The number of securities that have been issued during the block listing review period stated above includes 106,955 new Ordinary Shares issued on 10 January 2023 in connection with the exercise of employee share options under the CVS Group plc 2019-2023 SAYE Sharesave Scheme and a further 1,474 new Ordinary Shares issued on 10 January 2023 in connection with the exercise of employee options under the CVS Group plc 2018-2022 SAYE Sharesave Scheme .

Following the issue of these new Ordinary Shares, which rank pari passu in all respects with the Company's existing Ordinary Shares, the Company has a total issued share capital of 71,380,400 Ordinary Shares, each carrying one voting right. The Company holds no Ordinary Shares in treasury so the total number of voting rights is therefore 71,380,400.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Contacts:

CVS Group plc via Camarco

Richard Fairman, CEO

Jenny Farrer, Company Secretary

Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

Camarco (Financial PR)

Geoffrey Pelham-Lane +44 (0)7733 124 226

Ginny Pulbrook +44 (0)7961 315 138

Toby Strong +44 (0)7789 151 644

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRBLGDBIDBDGXB

(END) Dow Jones Newswires

January 11, 2023 11:31 ET (16:31 GMT)

CVS (AQSE:CVSG.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024